Business Wire
BusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessModerna shares surge after Phase 3 cancer results, sending short sellers deeper into lossesThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessModerna shares surge after Phase 3 cancer results, sending short sellers deeper into lossesThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessModerna shares surge after Phase 3 cancer results, sending short sellers deeper into lossesThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessModerna shares surge after Phase 3 cancer results, sending short sellers deeper into lossesThe Apex Times
Back to front
Target shares surge to a fresh high after earnings, revenue and outlook beat expectations
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 19, 11:45 AM EDT

Target shares surge to a fresh high after earnings, revenue and outlook beat expectations

Target forecast and operating performance in its fiscal second quarter came in above early expectations, lifting the company’s stock to a new peak. TJX Cos. slid even as peers reacted to the earnings season.

2 min readEditor-approved Apex article

Target Corp.’s stock jumped to a new high after the company reported fiscal second-quarter results that beat early views, with the retailer also pointing to strength in revenue, same-store sales and its outlook. The move came after trading began Wednesday, following the earnings release and accompanying guidance.

The financial highlights reported in advance of and immediately around the earnings news emphasized that Target easily cleared fiscal second-quarter earnings expectations. Alongside profit, the company’s results also reflected strength in sales and performance at stores open at least a year, a key metric retailers use to strip out the effects of new store openings and closures.

Target’s guidance, according to the same report, was also described as strong. Retail guidance matters because it indicates how management expects demand, promotional activity, inventory and margins to play out in the next quarter or fiscal period, often influencing how investors price the stock well beyond the headline earnings number.

In addition to profit and forward-looking comments, the report tied the market reaction to revenue and same-store sales coming in well, supporting the view that the company’s sales momentum was not only driven by category mix or seasonal timing. Same-store sales are watched closely because they act as a real-time proxy for whether shoppers are increasing spend at the core store base.

The broader sector reaction included weaker performance elsewhere. TJX Cos., another major retailer in off-price apparel and home merchandise, fell about 1.3% in the same window referenced by the report, underscoring that investors were separating outcomes across different retail business models rather than moving as a single basket.

For Target, a strong quarter and improved guidance typically suggest a favorable balance between demand and pricing. Retailers enter earnings season with investor focus on promotional intensity, inventory health and the sustainability of margins, all of which can change quickly when consumer spending shifts between categories or when freight and logistics costs move.

The reaction also points to the market’s emphasis on forward indicators. While the report characterizes Target’s guidance as strong, it does not detail the precise figures, the time horizon covered by the outlook, or the specific drivers management cited. That leaves uncertainty about how much of the beat was tied to cost control versus underlying demand strength.

Looking ahead, investors are likely to scrutinize whether Target can sustain the same-store sales pace described in the earnings news and whether management’s outlook remains robust as the company transitions through subsequent quarters. The next datapoints to watch will be additional earnings commentary, inventory and margin indicates in upcoming filings, and how rivals respond as earnings roll on.

Why It Matters

  • A beat on earnings is only part of the reaction; the report indicates investors also rewarded Target for revenue, same-store sales, and outlook.
  • Same-store sales are a core retail metric that helps the market assess ongoing demand versus the impact of store openings.
  • Strong guidance can reprice expectations for the company’s next-quarter performance, affecting valuation more than the single-quarter results.
  • The mixed reaction across retail peers, including TJX, suggests investors are evaluating business-model differences rather than treating the sector uniformly.

Sources

Key Facts

  • Target reported fiscal second-quarter results that beat early expectations for earnings.
  • The earnings report described strength in revenue and same-store sales.
  • Target’s guidance was characterized as strong in the earnings coverage.
  • Target’s stock jumped and reached a new high after the earnings news.
  • TJX Cos. was reported down about 1.3% in the same coverage window.

Retail & Consumer Related

Aug 19, 12:45 PM EDT
The Apex Times

Target tops Q2 estimates as sales rise 5.3%, and lifts its fiscal 2026 outlook

The retailer reported a quarter that beat earnings expectations, citing stronger in-store traffic, growth in digital sales, and improved performance across key categories. Management also pointed to tariff-related refunds supporting profitability and raised its fiscal 2026 guidance.

Target tops Q2 estimates as sales rise 5.3%, and lifts its fiscal 2026 outlook
The Apex Times